Congress should invest in AI and data science training to prepare the next generation of scientists for AI-supported drug development by integrating AI into biomedical research, supporting cross-disciplinary collaboration, and establishing best practices.

To Do: Invest in AI and Data Science Training for Drug Development

AI has the potential to transform drug development by enhancing productivity across the entire development pipeline, boosting biopharmaceutical innovation, accelerating the delivery of new therapies, and fostering competition to help improve public health outcomes.

Harnessing AI to Accelerate Innovation in the Biopharmaceutical Industry

Congress should increase public funding for initiatives such as ARPA-H’s programs to enhance AI-enabled drug discovery, NIH’s Bridge2AI Program to accelerate AI adoption in biomedical research, and NSF’s TIP support of AI-enabled platforms. 

To Do: Accelerate AI Adoption in Biopharma Research

Join ITIF's Center for Data Innovation for a panel discussion with leaders in medical research, medical regulation, and pharmaceutical development for a discussion on the future of data-driven medicine and how European policymakers can support health data research initiatives.

Using Data to Deliver Medical Breakthroughs at the Frontiers of Science

The White House’s AI Action Plan highlights how upgrading labs, data infrastructure, and research models is essential to unlock AI’s full potential in accelerating drug discovery and keeping the United States at the forefront of biopharmaceutical innovation.

America’s AI Action Plan: Implications for Biopharmaceutical Innovation

America's AI Action Plan: Implications for Biopharmaceutical Innovation

ITIF's Center for Data Innovation released a new report exploring opportunities to accelerate data-driven innovation in drug development and hosted a panel discussion about the ways data can make drug development faster, more efficient, and lead to new cures.

Accelerating Data-Driven Drug Development

Congress should fund NIH’s “All of Us” research program to improve the representativeness of datasets used in biomedical research.

To Do: Improve the Datasets Needed for Biomedical Research

AI can reduce the time it takes to synthesize and screen new drugs by 40 percent to 50 percent, reducing costs in those parts of the research process by as much as $26 billion annually.

Fact of the Week: Artificial Intelligence Can Save Pharmaceutical Companies Almost $54 Billion in R&D Costs Each Year

How Advances in Technology Can Leverage 21st Century Innovation in Health Care

BioTechX USA covers diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare, maintaining and fostering new relations with key stakeholders in the healthcare industry.

Sandra Barbosu chairs a session about AI and pharmaceuticals at the

Hynes Convention Center

Sandra Barbosu chairs a session about AI and pharmaceuticals at the 2025 BioTechX conference.

AI in Drug Discovery and Development

Related

To Do: Invest in AI and Data Science Training for Drug Development

Harnessing AI to Accelerate Innovation in the Biopharmaceutical Industry

To Do: Accelerate AI Adoption in Biopharma Research